Kiribati
Tuberculosis profile
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.017 (<0.01–0.026) 17 (9.5–26)
Mortality (HIV+TB only)        
Prevalence  (includes HIV+TB) 0.63 (0.27–1.1) 628 (270–1 132)
Incidence  (includes HIV+TB) 0.43 (0.35–0.52) 429 (349–517)
Incidence (HIV+TB only)        
Case detection, all forms (%) 80 (66–98)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 134 (40) Relapse 8 (80)
Smear-negative 122 (36) Treatment after failure 2 (20)
Smear-unknown / not done 0 (0) Treatment after default 0 (0)
Extrapulmonary 73 (22) Other 0 (0)
Other 9 (3)      
Total new 338   Total retreatment 10  
           
Other (history unknown) 0        
Total new and relapse 346   Total cases notified 348  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.7 1.4 1.4
Age < 15 8 41 25
Laboratories 2012
Smear (per 100 000 population) 2.0
Culture (per 5 million population) 49.6
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 94   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 89  
Retreatment 74  
TB/HIV 2012 Number (%)
TB patients with known HIV status 150 (43)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 4.9 (3.6–6.1) 23 (20–27)
MDR-TB cases among notified pulmonary
TB cases
13 (10–16) 2 (2–3)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed MDR-TB cases 0 0 0
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 16%
% Funded internationally 44%
% Unfunded 40%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data